根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号——回购股份》等相关规定，公司应当在每个月的前三个交易日内，公告截 至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 一、回购股份的进展情况 证券代码：000739 证券简称：普洛药业 公告编号：2026-01 普洛药业股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年11月18日召开第九届 董事会第十七次会议审议通过了《关于2025年第二次回购公司股份方案的议案》， 同意公司使用自有资金及金融机构回购贷款通过深圳证券交易所交易系统以集 中竞价交易方式回购公司股份，本次回购股份拟用于股权激励或员工持股计划。 本次回购股份价格不超过人民币23元/股，回购资金总额：不低于人民币18,000 万元（含）且不超过人民币36,000万元（含）。具体回购股份的数量和金额以回 购期限届满或者回购股份实施完毕时实际回购的股份数量和金额为准。回购期限 为自董事会审议通过回购股份方案之日起12个月内。具体内容 ...

Group 1 - The article highlights the development of Hengdian, known as the "Oriental Hollywood," which has become the world's largest film shooting base, generating an annual output value exceeding 35 billion yuan [5][10]. - Hengdian Group, founded 50 years ago, has diversified into various sectors including film and tourism, electronics, and pharmaceuticals, with total assets exceeding 100 billion yuan and six listed companies under its umbrella [5][15][17]. - The founder, Xu Wenrong, and his son, Xu Yong'an, are described as low-profile billionaires, emphasizing that the wealth of Hengdian Group belongs to the collective rather than individuals [6][18]. Group 2 - Hengdian's film industry strategy includes offering free shooting locations to attract film crews, which has led to significant growth in related services such as accommodation and dining, with the film industry generating 15.7 billion yuan in 2020 alone [10][11]. - The Hengdian Film City is projected to receive 15.24 million visitors in 2023, with revenues of 2.638 billion yuan, and 13.93 million visitors in 2024, with revenues of 2.867 billion yuan [11][12]. - Hengdian Film's revenue for 2024 is expected to be 1.971 billion yuan, with nearly 90% coming from cinema operations, while film investment and production contribute 10.3% [12]. Group 3 - Hengdian Group's assets include a general airport and a water plant, with a total revenue of 94.2 billion yuan in 2024 and a net profit of 3.124 billion yuan [17][18]. - The group has a unique corporate structure where ownership is held by community organizations, which has drawn interest from economists [19][20]. - The company is facing challenges in its magnetic materials sector, with market share declining to around 30%, and is adapting to the rise of short dramas in the film industry [24][25]. Group 4 - Hengdian Group is actively seeking transformation, with its photovoltaic sector achieving revenue of 11.47 billion yuan in 2025, a 43.6% increase, becoming a key business segment [25]. - The overall development of Hengdian has significantly improved local income levels, with residents' average annual income reaching 70,000 yuan [25].

证券代码：000739 证券简称：普洛药业 公告编号：2025-79 普洛药业股份有限公司 关于对下属公司担保的进展公告 二、担保事项履行的审议程序 公司于 2025 年 3 月 7 日、2025 年 4 月 17 日分别召开了第九届董事会第十 一次会议及 2024 年年度股东大会，审议通过了《关于对下属公司提供担保预计 的议案》，为下属 10 家子公司及孙公司在银行等金融机构的融资提供不超过人 民币 71 亿元的融资担保。本次对外担保额度授权期限为公司 2024 年年度股东大 会审议通过之日起至 2025 年年度股东大会召开之日止。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 12 月 11 日，普洛药业股份有限公司（以下简称"公司"）与中 国银行股份有限公司东阳支行（以下简称"中国银行"）签订《保证合同》（合 同编号：横店 2025 年人保字 213 号），同意为公司全资子公司浙江普洛家园药 业有限公司（以下简称"家园药业"）与中国银行签署的《商业汇票承兑协议》 （合同编号：横店 2025 年人承字 213 号）中的 ...

Core Viewpoint - Hengdian Group, known for its film and tourism industry, has diversified into various sectors including electronics and pharmaceuticals, with a total asset exceeding 100 billion yuan and a revenue of 942 billion yuan in 2024 [5][14]. Group 1: Film and Tourism Industry - Hengdian has become the largest film shooting base globally, generating over 35 billion yuan annually from its film and tourism industry [4]. - The company offers free filming locations to attract film crews, resulting in a loss of approximately 20 million yuan annually, but this strategy has significantly boosted the local film service and hospitality industries [8]. - In 2023 and 2024, Hengdian Film City is expected to receive 15.24 million and 13.93 million visitors, with revenues of 2.638 billion yuan and 2.867 billion yuan respectively [9]. Group 2: Business Diversification - Hengdian Group has evolved from a silk factory to a conglomerate with interests in film, electronics, pharmaceuticals, and modern services, holding six publicly listed companies [5][12]. - The electronics sector, particularly magnetic materials, once dominated the market but has seen a decline in market share to around 30% [23]. - The pharmaceutical sector, represented by Prolo Pharmaceutical, has been a significant contributor to the group's revenue since its inception [12]. Group 3: Financial Performance - In 2024, Hengdian Group reported a revenue of 942 billion yuan, with total assets reaching 1,039.78 billion yuan and a net profit of 3.124 billion yuan [14]. - The group has also ventured into financial services, holding a 4.99% stake in Zheshang Bank and recently listing Nanhua Futures on the Hong Kong Stock Exchange [14]. Group 4: Ownership Structure - Hengdian Group operates under a unique corporate structure where ownership is held by community organizations rather than individual shareholders, emphasizing collective wealth creation [21][22]. - The founder, Xu Wenrong, has consistently refused to appear on wealth rankings, asserting that the group's wealth belongs to the collective rather than individuals [16][21]. Group 5: Challenges and Future Outlook - The rise of short dramas poses a challenge to traditional film productions, prompting Hengdian to adapt by developing vertical filming spaces [23]. - The group is investing in new projects, including a 12GW battery production facility and the expansion of Hengdian Airport, with total investments in ongoing projects amounting to 11.678 billion yuan [23][24].

Group 1: Key News and Insights - The December 22 LPR remains unchanged at 3.0% for 1-year and 3.5% for 5-year loans, indicating a stable monetary policy environment [1][12] - The launch of the National Venture Capital Guiding Fund aims to attract diverse investments, targeting a total fund size of trillions by leveraging central government funds [1][22] - The National Development and Reform Commission (NDRC) has initiated 21 key measures to support the high-quality development of the Western Land-Sea New Corridor, emphasizing financial support and cooperation [1][15][16] Group 2: Market Overview - The domestic securities market showed mixed performance, with the Sci-Tech 100 index rising by 5.60%, while other major indices experienced declines [2][26] - The non-ferrous metals sector led the industry gains with a 6.43% increase, reflecting strong demand dynamics [2][28] Group 3: Buyback and Stake Increase - A total of 5 companies reported significant shareholder buybacks, with Kangnibei planning to increase its stake by over 1% of total shares [3][34] - 60 companies announced buyback plans, with 9 companies intending to repurchase more than 1% of their total shares, highlighting a trend of corporate confidence [3][36] Group 4: Investment Recommendations - In the technology sector, companies focused on artificial intelligence, semiconductor chips, and robotics are expected to outperform due to favorable policies and liquidity conditions [4][39] - The non-bank financial sector, particularly brokerage firms, is anticipated to benefit from a slow bull market, while insurance companies may see improved returns on long-term assets [4][40] - The copper market is expected to maintain a tight supply-demand balance, supporting price increases, while energy metals like lithium and cobalt remain attractive due to battery and storage demand [4][40] - The electric equipment sector is poised for growth driven by AI and renewable energy, indicating a robust future demand for power equipment [4][41] - Domestic consumption is projected to expand, with a focus on enhancing consumer spending capabilities [4][42]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 普洛药业股份有限公司（以下简称"公司"）于2025年11月18日召开第九届董事会第十七次会议审议通过 了《关于2025年第二次回购公司股份方案的议案》，同意公司使用自有资金及金融机构回购贷款通过深 圳证券交易所交易系统以集中竞价交易方式回购公司股份，本次回购股份拟用于股权激励或员工持股计 划。本次回购股份价格不超过人民币23元/股，回购资金总额：不低于人民币18,000万元（含）且不超 过人民币36,000万元（含）。具体回购股份的数量和金额以回购期限届满或者回购股份实施完毕时实际 回购的股份数量和金额为准。回购期限为自董事会审议通过回购股份方案之日起12个月内。具体内容详 见公司分别于2025年11月20日、2025年11月22日在《证券时报》和巨潮资讯网 （http://www.cninfo.com.cn）上披露的《第九届董事会第十七次会议决议公告》（公告编号：2025- 66）、《关于2025年第二次回购公司股份方案的公告》（公告编号：2025-67）及《关于2025年第二次 回购股份报告书》（公告编号：2 ...

格隆汇12月24日丨普洛药业(000739.SZ)公布，截至2025年12月22日，公司通过回购专用证券账户以集 中竞价方式回购公司股份1255万股，占公司目前总股本的1.08%，最高成交价为16.85元/股，最低成交 价为15.91元/股，成交总金额为2.04亿元（不含交易费用）。 ...

格隆汇12月24日丨普洛药业(000739.SZ)公布，截至2025年12月22日，公司通过回购专用证券账户以集 中竞价方式回购公司股份1255万股，占公司目前总股本的1.08%，最高成交价为16.85元/股，最低成交 价为15.91元/股，成交总金额为2.04亿元（不含交易费用）。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-78 本次回购符合公司回购股份方案及相关法律法规的要求。 二、其他说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 时间均符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第9号——回购股份》及公司股份回购方案的相关规定。 普洛药业股份有限公司 关于回购股份比例达到 1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年11月18日召开第九届 董事会第十七次会议审议通过了《关于2025年第二次回购公司股份方案的议案》， 同意公司使用自有资金及金融机构回购贷款通过深圳证券交易所交易系统以集 中竞价交易方式回购公司股份，本次回购股份拟用于股权激励或员工持股计划。 本次回购股份价格不超过人民币23元/股，回购资金总额：不低于人民币18,000 万元（含）且不超过人民币36,000万元（含）。具体回购股份的数量和金额以回 购期限届满或者回购股份实施完毕时实际回购的股份数量和金额为准。回购期限 为自董事会审 ...

2025年半年报显示，普洛药业的主营业务为医药行业、其他业务，占营收比例分别为：99.6%、0.4%。 | 市值(亿元) | 时间 | 2023Y | 2024Y | 2025前三 | | --- | --- | --- | --- | --- | | 194.62 | | | | 李度 | | | 营业收入 | 114.74 | 120.22 | 77.64 | | 机构持股(占流通盘) | (亿元) | | | | | 0家 | 归母净利润 | 10.55 | 10.31 | 7.00 | | 北向资金持股比例 | (亿元) | | | | | 6.18% | 净资产收益率 (%) | 17.99 | 15.91 | 10.59 | | (12月23日) | | | | | | 大股东质押率 | 毛利率 (%) | 25.66 | 23.85 | 25.02 | | 16.62% | 每股收益 | | | | | 最新监管情况 | (元) | | | | | 近一年无相关信息 | 经营活动现金流 | 10.31 | 12.09 | 7.74 | | | (亿元) | | | | | 公司品牌价值 | 应收 ...